Catabasis Pharmaceuticals, Inc. (CATB) Rose 3.8% Today. Why Do We Care?

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is a big mover this session as the company shares are trading 3.8% or 0.23 points higher from last closing price of $6.05, reaching $6.28 at last check. So what’s going on with CATB shares anyway? The price has risen in 2 of the last 5 days and is down -19.23% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 116,910 shares, and in total 131810 shares valued at $827767 were seen changing hands compared with 14900 shares valued at $90145 recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the CATB stock.

Catabasis Pharmaceuticals, Inc. (CATB) shares have notched a 3-month decline of about -19.23%, but has still advanced 38.44% year to date. By comparison, the stock sank -21.41% over the past 12 months, while it slipped -8.33% over the 1 month. The company’s market cap is around $69.94M, with its short interest ratio standing at 12.5%.

In the current trading session for CATB, the stock witnessed two major price actions, it rose to a high of $6.34 and was down as much as $6 at one point. The high recorded is very low when compared to their 52-week high which is $3.6. The 52-week high is now at -36.37 distance from current price. Their recent low of $9.76 represents a 72.5% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for CATB is $35, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

CATB‘s last price was down -4.89% as compared to the average trading price of 50 days recorded at $6.6 while enlarging the period to 200 trading days, the average closing price was $6.69. At present, there are 11.56 million in the total number of common shares owned by the public and among those 11.52 million shares have been available to trade. The percentage of shares being held by the company management was 1.87% while institutions stake was 43.7%. The company has generated negative returns on equity over the last 12 months (-59.1%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the CATB stock, there is another set of technicals that should be looked into and considered. Its -0.53% decline from moving average of $6.31 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.74 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Catabasis Pharmaceuticals, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $47.5 on shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), which corresponds to 657.37% upside potential than its current market price of $6.28 and implies potential despite the recent advance in the price. However, their current target price has fallen from $47.5 a month ago and is up handily from the consensus target of $36.6667 a quarter ago.

In the last five years, the EPS of the company has been roughly 17.1%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards CATB stock. Vanguard Group Inc. added position in the company after it grew 16% or 357,541 shares of its common stock. The hedge fund now owns 414,748 shares worth $2,604,617, SEC documents show. BlackRock Inc. shored up assets in the stock as 60208.86 shares have been purchased, increasing its stake by 186.8% to 172,679 shares which are currently valued at $1,084,424. In addition, RMB Capital Management LLC recently reported that it now owns 60,618 shares making a total of $380,681 based on the recent price. This refelects a change of -5.4% in their ownership.